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Abstract
Multiple endocrine neoplasia type 2B (MEN2B) is a highly aggressive thyroid cancer syndrome. Since almost all sporadic
cases are caused by the same nucleotide substitution in the RET proto-oncogene, the calculated disease incidence is 100–
200 times greater than would be expected based on the genome average mutation frequency. In order to determine
whether this increased incidence is due to an elevated mutation rate at this position (true mutation hot spot) or a selective
advantage conferred on mutated spermatogonial stem cells, we studied the spatial distribution of the mutation in 14
human testes. In donors aged 36–68, mutations were clustered with small regions of each testis having mutation
frequencies several orders of magnitude greater than the rest of the testis. In donors aged 19–23 mutations were almost
non-existent, demonstrating that clusters in middle-aged donors grew during adulthood. Computational analysis showed
that germline selection is the only plausible explanation. Testes of men aged 75–80 were heterogeneous with some like
middle-aged and others like younger testes. Incorporating data on age-dependent death of spermatogonial stem cells
explains the results from all age groups. Germline selection also explains MEN2B’s male mutation bias and paternal age
effect. Our discovery focuses attention on MEN2B as a model for understanding the genetic and biochemical basis of
germline selection. Since RET function in mouse spermatogonial stem cells has been extensively studied, we are able to
suggest that the MEN2B mutation provides a selective advantage by altering the PI3K/AKT and SFK signaling pathways.
Mutations that are preferred in the germline but reduce the fitness of offspring increase the population’s mutational load.
Our approach is useful for studying other disease mutations with similar characteristics and could uncover additional
germline selection pathways or identify true mutation hot spots.
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Introduction
Multiple endocrine neoplasia (MEN) type 2 is characterized by
thyroid cancer, variable penetrance of tumors or hyperplasia in
other endocrine organs and mutations in RET, the receptor
tyrosine kinase proto-oncogene ‘‘rearranged during transfection’’ [1,2].
The disease is transmitted in an autosomal dominant fashion.
MEN2 has two subtypes: MEN2A (OMIM 171400) accounts for
,90–95% of cases including a less penetrant sub-form (familial
medullary thyroid carcinoma, FMTC [2,3]), while MEN2B
(OMIM 162300) makes up the remaining ,5–10%.
MEN2B is characterized by a number of interesting genetic
features. (1) Half of all new cases result from sporadic mutations,
the vast majority (.95%) of which arise in the male germline
[4,5]. (2) The average age of the males who transmit a new
mutation to their children is greater than that of the average age of
all fathers (paternal age effect [4]). (3) The overwhelming majority
(95%, [6]) of new MEN2B mutations occur at the same nucleotide
site (c.2943T.C) resulting in the same amino acid substitution
(M918T) [7–9]. (4) Given that most new cases are caused by
mutations at this one site, the incidence of the disease implies that
the c.2943T.C nucleotide substitution frequency is several
hundred fold greater than the genome average mutation frequency
estimated from evolutionary sequence comparisons [10–15] and
direct disease incidence data [16,17] (see Text S1 for the detailed
calculation).
One possible explanation for the elevated frequency and
paternal age effect is that the c.2943T nucleotide site in RET is
unusually susceptible to undergoing the T.C transition mutation
compared to a T elsewhere in the genome (hot spot model). An
alternative possibility (germline selection model) is that the
c.2943T.C mutation is not unusually susceptible to mutation
but, as a result of the biochemical consequences of the MEN2B
amino acid substitution, the mutated self-renewing Ap spermato-
gonial stem cell (SrAp) is provided with a proliferative advantage.
(The designations Ap, and Ad which we discuss later in this
manuscript, refer to the cytological staining properties of the pre-
meiotic A-pale and A-dark spermatogonia, respectively; reviewed
in [18]).
PLoS Genetics | www.plosgenetics.org 1 February 2012 | Volume 8 | Issue 2 | e1002420There is considerable evidence that the two common Apert
syndrome FGFR2 mutations confer a germline advantage on
human SrAp (reviewed in [19,20]). Apert syndrome also shares
many of the same interesting genetic features as MEN2B.
Unfortunately, the biochemical role normally played by FGFR2
in mammalian SrAp function is virtually unknown [21–23]. One
advantage, then, to asking whether a germline selective advantage
is responsible for the elevated MEN2B mutation frequency and
paternal age effect is that wild type RET’s role has been
extensively studied in mouse testis and is known to be required
for the self-renewal of mouse spermatogonial stem cells (SSC,
reviewed in [24,25]). Our observation that the MEN2B mutation
does in fact confer a germline selective advantage allows a unique
insight into the molecular pathways involved in positive germline
selection in human males.
Results
MEN2B testes data
We follow our recently developed approach [26,27] by
measuring the spatial distribution of the MEN2B c.2943T.C
mutation in fourteen testes from normal men. We then
quantitatively test whether or not these distributions are consistent
with the hot spot model that predicts a uniform distribution of
SrAp with new mutations or the selection model that predicts these
mutant cells will be clustered. Both models assume that the germ
cells that undergo mutation are uniformly distributed in the testis
(for details supporting this assumption see Text S2). Each testis was
cut into 6 slices and each slice into 32 pieces of approximately
equal size. The amount of DNA in each piece was quantitated and
the frequency of mutant MEN2B molecules was established for
each piece using a highly sensitive modification of allele-specific
PCR called PAP [28] that gave a false positive rate of 4.7610
27
(based on analysis of ,2.7610
8 control genomes). For each testis
piece we estimate the mutation frequency per million genomes
(pmg). In Figure 1, this frequency is represented by a heat map
with colors ranging from light gray to dark brown. Dataset S1
contains mutation frequency estimates for each testis piece. In
Table 1, we use several statistics to summarize this data. For each
testis, we consider the average mutation frequency of all the pieces
(Av). Many testes have individual pieces with frequencies that are
very different from the average. For each testis, we also identify the
piece with the maximum mutation frequency (Mx). In order to
normalize for the varying average frequencies among different
testes, we consider the ratio of Mx to Av in each testis (Mx/Av). In
addition, we consider the fraction of testis pieces with mutation
frequencies less than 50 pmg (F,50); in Figure 1 these pieces are
colored light or dark gray.
Youngest samples
The youngest age group is made up of three individuals 19, 21,
and 23 years of age. For this age group, the Av ranges from 1 to
15 pmg. The Mx ranges from 13 to 65 pmg. Figure 1 shows that
all the pieces’ mutation frequencies are colored light gray
(,25 pmg), dark gray (25 to 50 pmg), or pink (50 to 500 pmg).
The few pieces colored pink in this age group are in the low end of
the pink range, since the one with the greatest frequency is only
65 pmg. For each testis the F,50 ranges from 95% to 100%.
Middle-aged samples
Six individuals, aged 36 to 68 years, comprise the middle-aged
group. For these testes, the Av ranges from 19 to 1,188 pmg. In
contrast to the youngest age group, each testis has a small number
of pieces with mutation frequencies that are several orders of
magnitude greater than the remaining pieces. The Mx ranges
from 643 to 48,884 pmg. These high frequency pieces are more
darkly colored in Figure 1, and are often clustered together in the
same slice or in adjacent slices. The sample with the lowest Av
(#59089) also has the lowest Mx, and the sample with the highest
Av (#854-2) also has the highest Mx. The Mx/Av ratio ranges
from 34 to 139. The F,50 fraction is still high, ranging from 76%
to 99%.
Both the Av and the Mx are greater for the middle-aged group
than the youngest age group. However, within the middle-aged
group there is no obvious correlation between frequency and age.
Indeed the testis with both the lowest Av and Mx is from a 45 year
old (#59089), and the testis with both the highest Av and Mx is
from a 54 year old (#854-2). So the extreme frequencies come
from individuals with ages in the middle of the group, and with
ages that are close to each other.
Oldest samples
The oldest age group containing five individuals aged 75 to 80
years is heterogeneous. Two of the individuals (#64302 and
#60954) have frequency values typical of the middle-aged group:
the Av are 75 and 203 pmg, the Mx are 4,372 and 6,673 pmg, the
Mx/Av are 58 and 33, and the F,50 are 98% and 84%. The
remaining three individuals (#60955, #57650, and #60507) have
much lower frequency values typical of the youngest age group:
the Av are 10 pmg or less, the Mx are 56 pmg or less, and the
F,50 are 99% and 100%. The three low frequency old samples
will be further discussed later in the Results section. For discussion
purposes, we define a testis as having ‘‘substantial’’ mutation
clusters if Mx is greater than 500 pmg: this group includes all of
the middle-aged samples and the first two from the oldest age
group, while excluding all of the youngest samples and the last
three from the oldest age group.
Hot spot model
Previously, we developed a model based on what is known
about human germ-line development and maturation to quanti-
Author Summary
Multiple endocrine neoplasia type 2B (MEN2B) is a highly
aggressive thyroid cancer syndrome. MEN2B offspring with
unaffected parents almost always received a new mutation
from the father. Moreover, this mutation is almost always
at the same nucleotide in the RET proto-oncogene. Thus
MEN2B’s incidence should equal the average single
nucleotide mutation frequency, but the observed inci-
dence is 100–200 times greater. One explanation is that
the mutation rate at the causal nucleotide is significantly
elevated above the genome average. Another is that
human testis stem cells acquiring this mutation have a
selective advantage over non-mutated ones and this
advantage increases the mutation’s frequency in the testis.
Computational analysis of our testis dissection and
mutation assay data rejects the hot spot but not the
selective advantage explanation. Because the normal RET
gene is known to be critical for mouse testis stem cell
function, we now have an important insight into what
biochemical pathways are altered by the MEN2B mutation
to provide this selective advantage in humans. Germline
selection explains the unexpectedly high incidence of
MEN2B, why the mutation’s origin is almost always in the
father, and why the probability a child is born with this
disease increases with the father’s age.
Human Germline Selection
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consistent with a hot spot model [26,27]. Here we briefly review
the model, apply it to the c.2943T nucleotide site in the RET gene,
and discuss a new variant to the model. The computer programs
to simulate all the models discussed here and elsewhere in the
paper can be found in Protocol S1.
The hot spot model has two phases that we call the growth-phase
and theadult-phase.The growth-phase modelsthe testisfrom zygote
formation to puberty. During this phase, divisions of the male germ-
line cells are symmetric and self-renewing, and the number of such
cells increases exponentially. Similar to a Luria and Delbruck
‘‘mutation jackpot’’ in bacteria [29], a mutation arising early in this
phase will be shared by more descendent germ-line cells than will
later mutations. The primordial germ cells migrate to the site of
gonad formation and form the seminiferous cords early in fetal
development [30,31] and since germ cells are expected to remain
physicallyclosetotheirancestorsoncethechordsareformed,further
celldivisionsofearlymutationscanresultinmutationclusters.There
are approximately 30 growth-phase generations [32].
The germ-cells originating during the growth-phase eventually
form the adult SrAp. These cells cycle throughout a man’s life
providing many opportunities for new mutations. The adult-phase
portion of the model considers the testis after puberty. During this
phase, the SrAp divide asymmetrically to produce a daughter
SrAp (self-renewal) and another daughter cell whose descendants,
after a few additional divisions, will produce sperm. In an adult
male, the SrAp divide every 16 days [33], and therefore from an
individual’s age we can estimate the number of adult phase
generations that his SrAp cells have experienced. In our model any
new mutation in the adult phase can produce only one mutant
SrAp self-renewing cell lineage. The model has only one free
parameter: the mutation rate per cell division.
Figure 1. Distribution of the MEN2B mutations in 14 human testes. Each testis is cut into 6 slices, and each slice is further dissected into 32
approximately equal pieces. The mutation frequency per million genomes (pmg) in each piece is represented by the color code in the lower left-hand
corner of the figure. Above each testis is the identification number and the age of the donor. The testes are organized by age: the left-hand column is
the youngest age group (19 to 23 years), the middle column is the middle-aged group (36 to 68 years), and the right-hand column is the oldest age
group (75 to 80 years).
doi:10.1371/journal.pgen.1002420.g001
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testis pieces. In order to test the hot spot model using the
maximum likelihood approach one would need to calculate the
probability, as a function of the model parameters, of the mutation
frequencies for all 192 testes pieces. Unfortunately, none of the
models we consider are amenable to such calculations. One could
estimate this probability function by counting the number of
computer simulations of the model that exactly match all 192
frequencies. However, the probability of exactly matching all 192
frequencies is so low that this approach is not feasible. The
goodness-of-fit strategy that we pursue instead is we test whether
there are values of the model parameters such that computer
simulations of the model can approximately match the three
summary statistics Av, Mx/Av, and F,50 simultaneously. These
statistics attempt to summarize both the mutation frequency and
the clustering observed in the testes. Say, for example, a model
predicts a more uniform distribution of frequencies than was
observed so that simulations which approximate the observed Av
statistic also feature much lower than observed Mx/Av ratios.
Since this model fails to capture both the mutation frequency and
the clustering observed in the testis, we would reject such a model.
Alternatively, suppose another model approximately matches the
three summary statistics simultaneously. Since this model
reproduces both the mutation frequency and the clustering
observed in the testis, we would declare such a model consistent
with the data.
Let us consider the example of testis #374-1 from a 62 year old.
The observed Av is 68 pmg (Table 1). In simulations, we vary the
mutation rate per cell division until we find the value of this model
parameter such that the simulated Av best matches the observed
Av. We simulate the model using this parameter value until we
have one million simulations where the simulated Av is within 5%
of the observed Av, and then we compare the other statistics for
these simulations (Table 2) to the actual data. For the observed
data the Mx/Av ratio is 85, while in 95% of simulations the ratio is
between 2.1 and 4.3. Indeed, in one million simulations this ratio is
always less than was observed in the data. Similarly the observed
Mx is 5,784 pmg, while in 95% of simulations the Mx is between
144 and 288 pmg. Since we only consider those simulations such
that the simulated Av is within 5% of the observed Av, the results
for the two statistics Mx and Mx/Av closely correspond. Since we
find the ratio Mx/Av more intuitive, we will only consider it
subsequently. Likewise, for the data the F,50 statistic is 90%,
while in 95% of simulations this fraction is between 25% and 35%.
In one million simulations this fraction is always less than was
observed in the data. Thus we are able to strongly reject the hot
spot model with p-value less than 10
26. In Table 2, we see the
same conclusion holds for the remaining seven testes with
substantial mutation clusters. Note that for testis #59089 in
95% of simulations the F,50 statistic is between 99% and 100%
because the Av (19 pmg, Table 1) is less than 50 pmg.
In the hot spot model, a mutation early in the growth phase
could produce a mutation cluster. In order to match the observed
Av, however, the inferred value of the mutation rate per cell
division model parameter is low enough such that mutations early
in the growth phase are rare. Since the SrAp divide every 16 days,
in a 62 year old male there have been approximately 500 times
more adult phase cell divisions than growth phase divisions [27]
and mutations in the adult phase do not produce mutation
clusters. Consequently, in simulations of the hot spot model that
match the observed Av the distribution of mutations is more
uniform than observed. Furthermore, even if one does not agree
with the modeling details, the youngest age group has markedly
lower Av and Mx statistics than the middle-aged group (Table 1).
Therefore, the increase in the mutation frequencies and the
growth of the mutation clusters occurs in the adult, not during
development.
Finally, we previously examined the distribution of a likely
neutral mutation in testis samples using the same approach [27].
We assayed a C to G mutation in the intron of the CAV1 gene on
chromosome 7. This presumably neutral mutation was studied in
testes 374-1 and 374-2 (62 years of age) and involved the same
DNA samples we used for the MEN2B analysis. The summary
statistics are identical for both testes (Av=3, Mx=20, Mx/
Av=6.67 and F,50=100%) and similar to the MEN2B data
from much younger donors. Simulations showed that the relatively
uniform distribution of mutations was consistent with the hot spot
model.
Symmetric hot spot model variant
Based on work in the mouse [34] and human [35], we also
consider a variant to the hot spot model where the SrAp in the
adult phase, independent of whether or not they have acquired the
disease mutation, may divide symmetrically. As in the original
model, each SrAp in the adult phase divides every 16 days, but
now there are three possible types of divisions (the probabilities of
these types sum to one). This variant introduces a second model
parameter q. With probability 1-2q, the SrAp cells divide
asymmetrically as in the original hot spot model. However, now
with probability q, the SrAp cells divide symmetrically producing
two SrAp cells: both daughter SrAp cells share any accumulated
mutations and since these cells remain physically near each other,
multiple symmetric divisions would produce a mutation cluster.
Also with probability q, in order to keep the number of SrAp cells
approximately constant [36,37], an SrAp cell can produce two
Table 1. MEN2B mutation frequency summaries from 14
testes.
Testis Age Av
a Mx
b Mx/Av
c F,50
d (%)
Youngest donors (19–23 years)
59056 19 15 65 4 95
63878 21 1 13 13 100
60832 23 10 59 6 99
Middle-aged donors (36–68 years)
62923 36 60 8,348 139 95
59089 45 19 643 34 98
854-2 54 1,188 48,884 41 76
374-1 62 68 5,784 85 90
374-2 62 103 5,843 57 88
60891 68 57 4,964 87 99
Oldest donors (75–80 years)
64302 75 75 4,372 58 98
60954 76 203 6,673 33 84
60955 76 10 55 6 99
57650 80 1 30 30 100
60507 80 10 56 6 99
aAv testis average mutation frequency per million genomes.
bMx maximum mutation frequency piece (per million genomes).
cMx/Av ratio maximum mutation frequency piece to testis average mutation
frequency.
dF,50 fraction pieces with mutation frequency less than 50 mutants per million
genomes.
doi:10.1371/journal.pgen.1002420.t001
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make sperm thus eliminating one SrAp cell lineage.
For a given mutation rate per cell division the Mx/Av and
F,50 statistics increase with the value of the symmetric
parameter q, therefore to make the test as conservative as
possible we only consider the case where q equals the maximum
possible value 0.5 (so one-half of the divisions produce two SrAp
cells and one-half produce two B spermatogonia). As in the test of
the original hot spot model, we simulate the model with the
mutation rate per cell division that best matches the observed Av
until we have one million simulations with Av within 5% of the
observed Av. We again consider sample #374-1. For the data the
Mx/Av ratio is 87, while in 95% of simulations this ratio is
between 5.6 and 12.9. For the data F,50 is 90%, while in 95%
of simulations this fraction is between 55% and 70%. The
symmetric variant to the hot spot model increases these statistics
greater than the level achieved by the original hot spot model, but
not as high as is observed for the data. Since in one million
simulations both the Mx/Av ratio and the F,50 fraction were
always less than was observed in the data, this variant is also
strongly rejected with p-value less than 10
26.A ss h o w ni n
Table 2, the same conclusion holds for the other testes with
substantial mutation clusters.
Selection model
Previously, in order to explain the mutation clustering for the
Apert syndrome mutations, we had proposed a role for selection
[26,27]. The selection model is based on the original hot spot
model, and adds a selection parameter p: at each adult phase
generation, a mutated SrAp divides symmetrically with probability
p and asymmetrically with probability 1-p (after a symmetric
division, each daughter SrAp reverts to asymmetric divisions until
the next rare symmetric division). A similar model was proposed
by Crow [38]. Unlike the symmetric hot spot model considered
above, non-mutated SrAp cells in the adult phase can only divide
asymmetrically. Since the SrAp daughter of an SrAp cell is
expected to remain near its progenitor, these rare symmetric
divisions can cause mutation clusters to form and grow locally over
time. The motivation for the selection model is that in model
organisms it has been shown that stem cells can switch from
asymmetric to symmetric divisions and back again, and that such
behavior can depend on factors intrinsic and extrinsic to the stem
cells [39,40].
Consider again sample #374-1 for the MEN2B mutation. The
selection model has two free parameters: the mutation rate per cell
division and the selection parameter p. With these two free
parameters, we can now try to match both the Av and the Mx. As
before, we only consider those simulations such that the simulated
Av is within 5% of the observed Av. For the data the Mx/Av ratio
is 85, and in 95% of simulations this ratio is between 26 and 92.
For the data the F,50 fraction is 90%, and in 95% of simulations
this fraction is between 86% and 93%. Therefore the selection
model is consistent with the data for this testis. The inferred
selection parameter p is 0.0084, so if the mutated SrAp cells divide
symmetrically approximately 1% of the time, this is sufficient to
form mutation clusters similar to what is observed in the testes.
Moreover, if we now take the inferred mutation rate per cell
division (4.4610
211) and set the selection parameter p equal to
zero, then simulations of the model produce mutation frequencies
similar to the already established genome averages [10–17],
implying that the mutation rate per cell division is not elevated at
this nucleotide [26,27].
Table 2. Hot spot model parameter and simulation results for those testes with substantial MEN2B mutation clusters.
Model parameter Mx/Av
a F,50
b (%)
Testis Age
Mutation rate per cell
division Data
Simulated 95%
range p-value Data
Simulated 95%
range p-value
Original hot spot model
62923 36 1.24610
27 139 1.9–6.1 ,10
26 95 38–49 ,10
26
59089 45 2.40610
28 34 2.4–4.9 ,10
26 98 99–100 1.0
854-2 54 1.38610
26 41 2.0–4.3 ,10
26 76 0–0 ,10
26
374-1 62 6.62610
28 85 2.1–4.3 ,10
26 90 25–35 ,10
26
374-2 62 1.01610
27 57 1.9–3.9 ,10
26 88 1–5 ,10
26
60891 68 5.00610
28 87 1.9–3.7 ,10
26 99 44–54 ,10
26
64302 75 5.82610
28 58 2.1–3.9 ,10
26 98 16–24 ,10
26
60954 76 1.54610
27 33 1.9–3.9 ,10
26 84 0–0 ,10
26
Symmetric variant
62923 36 1.24610
27 139 3.8–9.7 ,10
26 95 54–63 ,10
26
59089 45 2.40610
28 34 9.6–22.8 0.01 98 88–93 ,10
26
854-2 54 1.38610
26 41 2.5–5.2 ,10
26 76 0–1 ,10
26
374-1 62 6.62610
28 85 5.6–12.9 ,10
26 90 55–70 ,10
26
374-2 62 1.01610
27 57 5.7–12.3 4610
26 88 52–59 ,10
26
60891 68 5.00610
28 87 7.3–15.8 ,10
26 99 71–78 ,10
26
64302 75 5.82610
28 58 5.6–15.1 9610
26 98 53–72 ,10
26
60954 76 1.54610
27 33 4.3–8.9 10
24 84 35–44 ,10
26
aMx/Av ratio maximum mutation frequency piece to testis average mutation frequency.
bF,50 fraction pieces with mutation frequency less than 50 mutants per million genomes.
doi:10.1371/journal.pgen.1002420.t002
Human Germline Selection
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mutation clusters will grow as the man ages and the male mutation
bias since this growth is only in the male germline. The selection
model can also explain the elevated mutation frequencies and the
clustering observed for all the other testes with substantial
mutation clusters (results not shown). However, this model predicts
that the samples in the oldest age group will have the highest
mutation frequencies and the most intense mutation clusters, and
thus cannot explain the low mutation frequencies and lack of
mutation clusters observed in three of the testes from this age
group (see next heading).
We have also considered a ‘‘combined’’ model which merges
the symmetric variant to the hot spot model with the original
selection model: all SrAp randomly divide asymmetrically, divide
symmetrically or divide to produce two differentiated daughter
cells, but the mutant SrAp are more likely than the wild type SrAp
to divide symmetrically. However, we did not pursue this
combined model further since it introduces an additional model
parameter without improving the fit of the selection model.
Heterogeneous oldest age group
Our results for the oldest individuals were surprising in that
three (#60955, #57650, and #60507) of the five samples had
unexpectedly low levels of the c.2943T.C MEN2B mutation
similar to young testes (Table 1). One trivial explanation for such
low levels of mutation was germ cell degradation in these three
older samples and that this data should be discarded. To examine
this question we looked at the distribution of a different mutation.
We used the version of our assay originally designed for the Apert
syndrome c.755C.G mutation [26,27] on the same 14 testes we
studied for the MEN2B mutation (plus one 21 year old sample,
#63205, which we had not studied for MEN2B). Figure S1 shows
the Apert syndrome mutation distribution for all the testes and
Dataset S2 contains the mutation frequency estimates for every
piece. Table 3 summarizes the mutation frequency statistics for
each testis and Figure 2 shows the mutation distribution for the
five testes in the oldest age group. The results showed substantial
Apert mutation clusters in all five older testes including those with
the fewest MEN2B mutations. Therefore general germ cell
degradation in the three testes cannot explain the heterogeneity
in the MEN2B data. Another observation, which will play a part in
the subsequent modeling, is that for the middle-aged group of
testes the median Av is ,4-fold higher and the median Mx is ,3-
fold higher for the Apert mutation compared to the MEN2B
mutation (see Table 1 and Table 3).
Selection model incorporating cell death
To try and explain the MEN2B data on the oldest age group,
we concluded that the only acceptable model modification was to
incorporate age-dependent cell death. Researchers have shown
that the number of SrAp cells decreases as men grow old [36]:
from the ages of 31–40 to 61–70 there is a slight decrease from 162
cells per mm
2 of seminiferous tubule cross section to 120 per mm
2,
but from the ages of 61–70 to ages 81–90 there is a much more
rapid decrease from 120 mm
2 to 57 per mm
2. There is a similar
pattern of decrease for the A-dark spermatogonia (Ad). Believed to
act as ‘‘reserve’’ stem cells, the Ad remain quiescent until the
number of SrAp cells is sufficiently diminished to activate the Ad
to replace the SrAp [41]. Since the Ad have not been cycling as
frequently as the SrAp until this point, they are less likely to have
acquired any mutations, and thus the pool of SrAp cells is
replenished with a fresh supply of primarily non-mutated cells. We
have incorporated cell death into the selection model by assuming
that all SrAp, whether or not they are mutated, die at the same
rate. The details of this new model can be found in Text S3.
The selection model incorporating cell death can explain all of
the testes data for both MEN2B and Apert syndrome. For those
testes with substantial MEN2B mutation clusters, as before, we
varied the mutation rate per cell division and the selection
parameter to try to match both the Av and the Mx, and we only
considered those simulations such that the simulated Av was
within 5% of the observed Av. Table 4 shows that this model is
consistent with these testes. For those testes without substantial
mutation clusters, we did not fit each testis separately (many low
values of the model parameters would suffice) but rather for a
given age and set of parameter values we simulated the model
many times to see how often the simulations were typical of a
young donor and how often they were typical of a middle-aged
donor (see Text S3 for details). For MEN2B, we found that when
we set the selection parameter at the low end of the range in
Table 4 then most simulations of an older individual were typical
of a young donor. However, when we increased the selection
parameter to the median value in Table 4 then most simulations of
an older individual were typical of a middle-aged donor. Thus a
relatively slight variation in the selection parameter between
individuals can explain the heterogeneity in the older donors for
MEN2B. As for the Apert syndrome mutation, the Av and Mx
values in Tables 1 and 3 are greater for the Apert mutation than
the MEN2B mutation, leading to slightly higher inferred values for
the selection parameter for the Apert mutation (see Table S1).
When we increased the selection parameter to the median value
Table 3. Apert syndrome c.755C.G mutation frequency
summaries from 15 testes.
Testis Age Av
a Mx
b Mx/Av
c F,50
d (%)
Youngest donors (19–23 years)
59056
e 19 16 4,000 250 99
63205
f 21 1 8 8 100
63878 21 2 12 6 100
60832
e 23 1 9 9 100
Middle-aged donors (36–68 years)
62923 36 3 2,936 979 99
59089
e 45 160 8,000 50 93
854-2
e 54 680 47,000 69 93
374-1
e 62 380 27,000 71 88
374-2
e 62 67 7,000 104 97
60891 68 861 45,075 52 95
Oldest donors (75–80 years)
64302 75 166 6,847 41 96
60954 76 25 2,045 82 97
60955 76 132 18,327 139 95
57650 80 446 36,652 82 88
60507 80 621 30,418 49 97
aAv testis average mutation frequency per million genomes.
bMx maximum mutation frequency piece (per million genomes).
cMx/Av ratio maximum mutation frequency piece to testis average mutation
frequency.
dF,50 fraction pieces with mutation frequency less than 50 mutants per million
genomes.
epreviously published [26].
ftestis not studied for MEN2B.
doi:10.1371/journal.pgen.1002420.t003
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simulations of an older individual were typical of a middle-aged
donor in agreement with Table 3. The slight increase in the value
of the selection parameter for Apert syndrome compared to
MEN2B can explain the difference in the oldest age groups for
these two mutations. Finally for MEN2B and the youngest donors,
even using the greatest values of both the mutation rate per cell
division and the selection parameter from Table 4, almost all
simulations of a 23 year old are typical of a young donor in
agreement with Table 1. For these parameter values, the
probability of a substantial mutation cluster developing in a 23
year old is very small due to the relatively low number of adult
phase generations.
Discussion
A highly sensitive DNA amplification method to detect the
MEN2B c.2943T.C mutation was combined with a dissection
protocol allowing construction of a three dimensional representa-
tion of the anatomical distribution of the mutations in the testis.
For all the middle-aged testes we studied (ages 36 to 68), the
MEN2B mutation frequency was greater than expected based on
the genome average mutation frequency. Further, the mutations
were clustered: each of these testes had a small number of pieces
with mutation frequencies several orders of magnitude greater
than the remaining pieces.
Moreover, for the younger testes (aged 18 to 23) there were
almost no mutations suggesting that the clusters in the middle-
aged donors are not due to mutations arising early in development
but grew during adulthood. The hot spot model where SrAp
divisions are always asymmetric was rejected (p-value,10
26),
because it could not reproduce these clusters. A new symmetric
variant to the hot spot model in which all SrAp, regardless of
whether or not they are mutated, sometimes randomly divide
asymmetrically, divide symmetrically to make two SrAp cells or
divide to produce two differentiated daughter cells, was also
rejected.
The explanation of our data requires some form of germline
selection so that mutant SrAp are able to increase in frequency
locally and grow clusters. The form of selection we considered is
that wild type SrAp always divide asymmetrically, while mutant
SrAp generally divide asymmetrically but, critically, occasionally
divide symmetrically to produce two SrAp. Our data on testes with
substantial mutation clusters fits this model well. The inferred
mutation rate per cell division for the selection model is not
elevated above that inferred from the genome average mutation
frequency using evolutionary sequence comparisons [10–15] and
direct disease incidence data [16,17]. Germline selection can also
explain the paternal age effect and the male mutation bias, two
characteristics MEN2B shares with some other diseases with
elevated frequencies (reviewed in [19,20,38,42,43]).
These results are similar to those we found previously when
studying the mutations that cause Apert syndrome [26,27]. One
difference between the MEN2B and Apert mutations is that in
older donors (ages 75 to 80) the MEN2B mutation frequency was
heterogeneous: some of the older testes were like the middle-aged
testes while other older testes were like the younger testes. We were
able to explain this observation by incorporating data [37] on age-
dependent spermatogonial cell death in the selection model and
allowing a slight variation in the value of the selection parameter
between individuals. For the Apert mutation, all of the older testes
were like the middle-aged testes. A greater value for the selection
parameter for the Apert mutation compared to the MEN2B
mutation (supported by both a greater median value for the
average mutation frequency (Av) and a higher median value for
the maximum piece mutation frequency (Mx) for the Apert
mutation) can explain this difference.
MEN2B testicular phenotypes
The MEN2B mutation causes aggressive malignant tumors in
the thyroid gland during early childhood and later-appearing
tumors in the adrenal glands (pheochromocytoma) as well as other
kinds of abnormal growths [2,44] but testis cancer has not been
reported as a feature of men with the disease ([2] updated 5/4/
2010). A study of the most common type of human testis cancers
(seminomas) and rare spermatocytic seminomas both failed to find
tumors carrying the MEN2B mutation [45,46]. Using a mouse
model of MEN2B [47] testicular cancer was not observed in either
homozygotes (Ret
MEN2B/MEN2B) or heterozygotes Ret
MEN2B/+. Men
with MEN2B disease (carrying the mutation in all their cells) can
father children with MEN2B [4], and Ret
MEN2B/MEN2B and
Ret
MEN2B/+ mice also show normal sperm production [47]. These
results indicate that the functional properties of the MEN2B
protein are consistent with normal spermatogenesis and spermio-
genesis but do not contribute to germ cell tumor formation. On
Figure 2. Distribution of the Apert syndrome c.755C.G
mutation for the oldest age group (75–80 years). These are the
same testes as the oldest age group shown in Figure 1. For the Apert
mutation, unlike the MEN2B mutation in Figure 1, all of the older testes
have substantial mutation clusters. The color code is the same as in
Figure 1.
doi:10.1371/journal.pgen.1002420.g002
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+/+ mice by
overexpressing glial derived neurotrophic factor (GDNF), the
major ligand of RET in the testis, results in germ cell tumors that
are seminoma-like and led to disruption of normal spermatogen-
esis [48]. We conclude that the activating effect of the MEN2B
mutation on RET function in SrAp cells is minimal compared to
RET function in the mouse germline when continually activated
by GDNF. A sufficient selective advantage relative to wild type
SrAp is necessary to allow cluster formation yet the achievement of
this advantage by MEN2B SrAp cells still allows the production of
the differentiating daughter spermatogonia needed for normal
sperm production and transmission to the next generation.
How RET functions in self-renewing germ cells
To understand how MEN2B RET alters the normal function of
SrAp cells we must consider RET’s normal biochemical properties
(reviewed in [44,49,50]). RET is a receptor tyrosine kinase
activated after forming a complex with both GDNF and a member
of the GDNF-family a co-receptors anchored to the cell surface
(GFRa1). Complex formation results in RET dimerization and
induction of RET’s tyrosine kinase activity resulting in trans-
autophosphorylation of critical tyrosines in each RET monomer’s
intracellular domain. Interactions between these phosphorylated
tyrosine docking sites and adapter or signaling proteins initiates a
variety of downstream signaling pathways.
Wild type RET functions in a wide variety of cells and tissues
including the central and peripheral nervous system, during the
development of the kidney and in a variety of other organs
(including testis). Whether cell proliferation, cell survival, differ-
entiation or a myriad of other cell processes are stimulated or
inhibited by RET activation depends on which RET protein
isoforms are expressed, the specific cell types involved, their
developmental stage and the expression patterns of many
additional proteins that function in downstream signaling
pathways including Ras/MAPK, SFK and PI3K/AKT among
others (reviewed in [44,49,50]). Since published work on RET’s
direct role in the adult human testis is extremely limited we look to
studies of the mouse’s RET protein for help in understanding how
a new MEN2B mutation in a wild type testis might lead to a
germline selective advantage of the newly mutated cell in humans.
RET signaling is critical for the continuing self-renewal of
spermatogonial stem cells in the mouse (SSC) and thus
spermatogenesis (reviewed in [23,24]). Self-renewal requires
balancing the number of SSC divisions that lead to more SSCs
against SSC divisions that produce precursors of differentiating
spermatogonia so that both the number of stem cells and the
amount of sperm production is sustained throughout life
[23,25,51–53]. We suggest that pathways involved in maintaining
this balance are subtly modified by the M918T mutation.
Using mouse knockout and overexpression models, experiments
on Gdnf, Gfra1o rRet have shown that all three genes are critical for
SSC self-renewal. Other experiments using testis cell cultures
grown in serum-free chemically defined media showed that GDNF
alone could promote SSC self-renewal for long periods of time
[54] implicating RET as being critical for this process. Transgenic
mice carrying a phenylalanine mutation (Y1062F) at one of RET’s
critical tyrosines [55] lose all germ cells within three weeks
suggesting that Y1062 function influences this process.
Studies in vitro using mouse undifferentiated spermatogonial cell
cultures grown in serum-free media showed that the PI3K
(phosphatidylinositol-3 kinase)/AKT and SFK (SRC family
kinases) pathways play an important role in SSC self-renewal
[23,25,51]. It has also been proposed that RAS activation is
involved in SSC self-renewal [53].
The effect of the human MEN2B mutation on RET
function
The biochemical consequences of the M918T mutation on
RET function have been studied extensively in a variety of tissues
and cell types but not the germline (reviewed in [44,49,50,56]).
The M918T protein can be activated as a monomer even before
being inserted into the cell membrane unlike wild type RET,
which normally requires dimerization through ligand binding at
the cell surface. The mutant protein also alters its own pattern of
tyrosine autophosphorylation in the intracellular domain of RET.
This can result in weakened signaling for some downstream
pathways and/or activation of pathways not normally signaled by
wild type RET. Notably, the M918T mutant protein also shows
constitutively high levels of tyrosine phosphorylation especially at
Y1062, the docking site that influences SSC self-renewal in mice.
Proteins that normally bind to Y1062 in wild type RET might be
expected to signal the PI3K/AKT, and/or RAS/MAPK
downstream pathways at unusually high levels in the testis.
Constitutive phosphorylation of the RET binding site (Y981) for
Table 4. Selection model incorporating cell death model parameters and simulation results for those testes with substantial
MEN2B mutation clusters.
Model parameters Mx/Av
a F,50
b (%)
Testis Age
Mutation rate per cell
division Selection parameter Data
Simulated 95%
range Data
Simulated 95%
range
62923 36 3.9610
211 0.020 139 41–149 95 92–97
59089 45 7.0610
211 0.012 34 19–61 98 91–98
854-2 54 9.1610
211 0.013 41 21–79 76 69–80
374-1 62 4.4610
211 0.0084 85 26–92 90 86–93
374-2 62 4.9610
211 0.0088 57 28–91 88 84–92
60891 68 1.5610
211 0.010 87 51–161 99 93–99
64302 75 2.0610
211 0.012 58 43–160 98 92–98
60954 76 1.2610
210 0.011 33 18–61 84 73–84
aMx/Av ratio maximum mutation frequency piece to testis average mutation frequency.
bF,50 fraction pieces with mutation frequency less than 50 mutants per million genomes.
doi:10.1371/journal.pgen.1002420.t004
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signaling.
Based on the role of RET in mouse SSC self-renewal we
propose that the M918T mutation modifies the signal transduced
from GDNF activated RET downstream through the SFK, PI3K/
AKT and possibly RAS pathways leading to the production of
mutation clusters. In the human context self-renewal can be
achieved by balancing asymmetric and the two types of symmetric
SrAp cell divisions as described by our models. The details of how
the SFK, PI3K/AKT and possibly RAS pathways enable normal
SrAp self-renewal in the germline and how the MEN2B mutation
alters these processes to confer a selective advantage to mutated
SrAp cells are yet to be determined.
Similarities between the MEN2B and Apert syndrome
mutation processes
Apert syndrome (OMIM 101200) is characterized by premature
closing of the sutures between the bones of the skull (craniosyn-
ostosis) due to gain of function mutations in the receptor tyrosine
kinase fibroblast growth factor receptor 2 gene (FGFR2), one of
four such receptors (FGFR1-4). The disease manifestations of
MEN2B and Apert syndrome are very different yet, like MEN2B
mutations, new Apert syndrome germline mutations also arise at
an unexpectedly high frequency (100–1,000 times that expected) at
a limited number of nucleotide sites (c.755C.G or c.758C.G),
virtually always occur in the male parent and exhibit a paternal
age effect (reviewed in [19,38,42,43,57]). Both Apert syndrome
mutations are distributed in testes as clusters rather than uniformly
([26,27] and this paper) and, together with other results [22,38,58–
61], support the idea that the unexpectedly high frequency of the
two Apert nucleotide substitution mutations and paternal age
effect results from a selective advantage acquired by mutated SrAp
cells over wild type cells.
Relevant similarities between RET and FGFR2 cell
signaling
Normal FGFR2 activation follows ligand binding to a subset of
the 18 human fibroblast growth factors [62], dimerization and
transphosphorylation. FGFR2 downstream signaling pathways
can influence cell proliferation, cell survival, differentiation and a
myriad of other cell functions in many different cell and tissue
types (reviewed in [63–67]).
Unfortunately, compared to RET, virtually nothing is known
about the downstream signaling pathways stimulated by activated
FGFR2 in mouse undifferentiated spermatogonial cultures or
other germ cells [21–23] although the addition of one of the
fibroblast growth factors (basic bFGF/FGF2), also a ligand of
FGFR2, is required for the self-renewal of mouse SSC in cell
culture (reviewed in [23]).
The two Apert syndrome mutations increase FGFR2’s FGF
ligand binding affinity and alter ligand specificity. Consequently,
FGFR2 has an unusually long residence in the cell membrane
during which time interactions with other proteins could produce
abnormally persistent downstream activation signals [63–66,68–
72]. Whether mouse or human SSC self-renewal also involves
FGFR2 signaling through the PI3K/AKT and SFK pathways or
some other pathway is not known although activated FGFR2 can
signal through the Ras/MAPK and PI3K/AKT (and possibly
SFK [73]) pathways in non-germline cells and tissues.
More information about the normal function of RET and
FGFR2 in spermatogonia are needed to provide an explanation
for how both these disease mutations might perturb the signaling
landscape to elicit a positive germline selective advantage. Our
discovery that MEN2B seems to provide a spermatogonial
selective advantage will make it possible to leverage the
information on the function of RET with regard to what may
be learned about FGFR2 and vice versa and to find out the
similarities and differences between the pathways that lead to a
germline selective advantage in each case.
The significance of germline selection
In a theoretical analysis twenty years ago Hastings [74,75]
studied the consequences of germline selection on the mutational
load of a population. The focus of Hastings’ work was primarily
concerned with very rare recessive alleles already existing in the
population but primarily found only in heterozygotes. Hastings
suggested that germline genetic events leading to loss of
heterozygosity (e.g. gene conversion, mitotic crossing over) in an
individual heterozygous for the rare allele could produce
premeiotic germ cells homozygous for this allele. If homozygosity
for this allele was selectively disadvantageous in both the germline
and at the level of an individual the potential mutational load of
this allele on the population would be significantly reduced.
Hastings also suggested that rare recessive but selectively
advantageous alleles could increase in frequency in the population
by the same reasoning. Finally, he recognized the possibility that
some mutations may have a germline selective advantage but also
a selective disadvantage for individuals in the population. This
would create what he called a ‘‘mitotic drive’’ system and increase
the mutational load of the population. The MEN2B and Apert
mutations seem to be realizations of this idea. In both examples
the mutation incidence and the magnitude of the paternal age
effect are markedly greater than would be expected simply by an
increase in the mutation rate per cell division.
There are additional candidate de novo disease mutations at
other loci that might also provide a germline selective advantage
(reviewed in [19,20,38,42,43]) to spermatogonia. Of course the
ability of any such mutation to increase the human mutational
load depends upon not significantly interfering with the state of
differentiation of the stem cell so as to permit mutant sperm
formation and transmission to the next generation. As we learn
more about the germline signaling pathways involved and the
effect of specific mutations on those pathways it may be possible to
identify other mutations that might either provide a selective
advantage and be transmitted to the next generation or those that
will not be transmitted to the next generation in spite of their
germline selective advantage because they interrupt a fundamental
aspect of spermatogonial differentiation. The testis dissection
method can be useful in studying these questions in animals.
Materials and Methods
Human subjects
The study was approved by the Institutional Review Board of
the University of Southern California. It involved anonymous
organ donors and was certified as exempt: 45 CFR 46.101 (b) (4).
Source of testes
Testes were obtained from the National Disease Research
Interchange (NDRI, Philadelphia, PA). No donors were accepted
if they had been treated with drugs known to interfere with normal
spermatogenesis. All samples were frozen within 10–12 h after
death.
Testis dissection
Details of the dissections, DNA isolation and quantitation of the
amount of DNA in each testis piece have been published [26,27].
Human Germline Selection
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We modified a highly specific amplification assay that uses
dideoxy-terminated PCR primers in a reaction buffer with added
pyrophosphate (pyrophosphorolysis-activated PCR, or PAP [28]).
In general our assay is almost identical to that used in our earlier
work [26,27,61]. Each MEN2B amplification reaction contained
20 mM HEPES (pH 7.0), 30 mM KCl, 50 mMN a 4PPi, 2 mM
MgCl2,8 0mM of each dNTP and 160–320 nM of each primer.
The MEN2B specific primer sequences were 59TGCGTGGTG-
TAGATATGATCAAAAAGGGATTCAATTGCCGdd39 (Bio-
search) and 59 TCCATCTTCTCTTTAGGGTCGGATTCCA-
GTTAAATGGACdd 39 (IDT). Each reaction also included 2 mM
Rox, 0.2 X Syber Green I, 0.04 unit/uL TMA31FS DNA
polymerase (Roche Molecular Systems), and DNA containing
25,000 genomes from the testis piece. [Research samples of
Tma31FS DNA polymerase may be obtained from Dr. Thomas
W. Myers, thomas.myers@roche.com, Director, Program in Core
Research, Roche Molecular Systems, Inc., 4300 Hacienda Drive,
Pleasanton, CA 94588]. PCR was carried out in 384 well plates
using either a Roche LightCycler 480 or a Applied Biosystems
7900. The cycling conditions (Roche LightCycler 480) were: initial
denaturation 1 min, 94uC and 130 cycles of 6 s, 94uC and 1 min,
73uC. Initial denaturation using the Applied Biosystems 7900 was
1 min, 94uC followed by 130 cycles of 6 s, 94uC and 1 min 15 s,
74.4uC. In this paper the false positive rate in the MEN2B assay
was 4.7610
27 based on an analysis of 269 million wild type
genomes.
Mutation counting strategy
We initially estimated the MEN2B mutation frequency using
ten reactions (25,000 genomes per reaction) from every testis piece.
If less than 5/10 reactions were positive we took that number as an
estimate of the mutation frequency (after Poisson correction). If 5
or more reactions were positive we repeated the experiment using
diluted samples of the piece until fewer than 50% were positive.
The presence of a single mutant molecule in any reaction was
detected by examining the kinetics of fluorescence increase as a
function of cycle number using quantitative PCR and evaluation
of the PCR product melting profile. Sample PAP data has already
been published as a supporting figure in an earlier publication
[27].
In every experiment 20 negative controls each contained 25,000
human blood genomes from unaffected individuals (Promega).
Twenty positive controls each contained 25,000 control blood
genomes and an average of 0.5 or 1 genome of MEN2B DNA with
the c.2943T.C mutation (kindly provided by Dr. Robert
Hofstra). The estimate of the total testis mutation frequency
(mutations per million genomes) was the average of the frequencies
of the pieces weighted by the number of genomes in those pieces.
Quantitative modeling and testing
The computer code and instructions to simulate all of the
models can be found in Protocol S1.
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figure. Above each testis is its identification number and the age of
the donor. The testes are organized by age: the left-hand column is
the youngest age group (19 to 23 years), the middle column is the
middle-aged group (36 to 68 years), and the right-hand column is
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